Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
1,054.29
-7.90 (-0.74%)
At close: Dec 16, 2025, 4:00 PM EST
1,053.94
-0.35 (-0.03%)
After-hours: Dec 16, 2025, 7:59 PM EST
Eli Lilly Revenue
Eli Lilly had revenue of $17.60B in the quarter ending September 30, 2025, with 53.87% growth. This brings the company's revenue in the last twelve months to $59.42B, up 45.41% year-over-year. In the year 2024, Eli Lilly had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$59.42B
Revenue Growth
+45.41%
P/S Ratio
15.94
Revenue / Employee
$1,264,251
Employees
47,000
Market Cap
943.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
| Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
| Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
| Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
| Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
| Dec 31, 2019 | 22.32B | 826.20M | 3.84% |
| Dec 31, 2018 | 21.49B | 1.52B | 7.61% |
| Dec 31, 2017 | 19.97B | -1.25B | -5.88% |
| Dec 31, 2016 | 21.22B | 1.26B | 6.33% |
| Dec 31, 2015 | 19.96B | 343.10M | 1.75% |
| Dec 31, 2014 | 19.62B | -3.50B | -15.13% |
| Dec 31, 2013 | 23.11B | 509.70M | 2.25% |
| Dec 31, 2012 | 22.60B | -1.68B | -6.93% |
| Dec 31, 2011 | 24.29B | 1.21B | 5.25% |
| Dec 31, 2010 | 23.08B | 1.24B | 5.68% |
| Dec 31, 2009 | 21.84B | 1.46B | 7.19% |
| Dec 31, 2008 | 20.37B | 1.74B | 9.33% |
| Dec 31, 2007 | 18.63B | 2.94B | 18.75% |
| Dec 31, 2006 | 15.69B | 1.05B | 7.14% |
| Dec 31, 2005 | 14.65B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
LLY News
- 10 hours ago - Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly - CNBC
- 13 hours ago - Is Eli Lilly a Buy Before 2026? - The Motley Fool
- 14 hours ago - Lilly to participate in J.P. Morgan Healthcare Conference - PRNewsWire
- 17 hours ago - Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars - Benzinga
- 19 hours ago - Where Will Eli Lilly Be in 10 Years? - The Motley Fool
- 1 day ago - 2 Predictions for Eli Lilly in 2026 - The Motley Fool
- 1 day ago - Eli Lilly's Obesity Drug Dominance Still Underpriced By Market, Bank of America Says - Benzinga
- 1 day ago - Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade) - Seeking Alpha